Transrectal high-intensity focused ultrasound with the Sonablate 500 for the treatment of prostate cancer.
- Author:
Jun LU
1
;
Zhao-yang CHEN
;
Wei WANG
;
Yuan-feng ZHANG
;
Xiao-fu QIU
;
Li-chao ZHANG
;
Wei-lie HU
;
Wen-feng XU
;
Zhang-qun YE
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; blood; Prostatic Neoplasms; blood; pathology; therapy; Treatment Outcome; Ultrasound, High-Intensity Focused, Transrectal
- From: National Journal of Andrology 2007;13(11):1005-1008
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical effect of transrectal high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer (PCa).
METHODSA total of 57 PCa patients, 27 localized and 30 advanced, underwent transrectal HIFU with the Sonab- late 500, the localized group treated by transrectal HIFU only, while the advanced group by transrectal HIFU combined with androgen ablation.
RESULTSFor the HIFU treatment, the mean operating time, hospital stay and follow-up were 111 mm (ranging from 86 to 153 mm), 3.2 days (ranging from 2 to 18 days) and 18 months (ranging from 6 to 30 months), respectively. The biochemical disease-free rates at 1, 2 and 3 years in the localized group were 86%, 81% and 79%, respectively. While in the advanced group, the serum prostate specific antigen (PSA) was < 4.0 microg/L in 26 cases ( < 0.51 microg/L in 20) and the prostate volume decreased more than 50% in 21 cases after treated for an average of 8 months (ranging from 3 to 24 months). After transrectal HIFU prostate ablation, the prostate volume reduced, serum PSA lowered, Qmax raised and IPSS improved significantly (P < 0.05). No serious complications occurred including severe urethrorectal fistula and incontinence.
CONCLUSIONTransrectal HIFU is a safe, effective and minimally invasive therapy for patients with prostate cancer.
